DISCOVER: much accomplished, but not yet for all
- PMID: 32711780
- PMCID: PMC7377696
- DOI: 10.1016/S0140-6736(20)31530-0
DISCOVER: much accomplished, but not yet for all
Comment on
-
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.Lancet. 2020 Jul 25;396(10246):239-254. doi: 10.1016/S0140-6736(20)31065-5. Lancet. 2020. PMID: 32711800 Free PMC article. Clinical Trial.
References
-
- Mayer K, Molina JM, Thompson MA. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396:239–254. - PMC - PubMed
-
- Onyema O, Podzamczer D, Salazar LC, et al. Longer term efficacy and safety of F/TAF and F/TDF for HIV PrEP: DISCOVER trial week 96 results. Conference on Retroviruses and Opportunistic Infections; Boston, MA, USA; March 8–11, 2020 (abstr 92).
-
- UNAIDS . Joint United Nations Programme on HIV/AIDS; Geneva: 2020. We've got the power: women, adolescent girls and the HIV response.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical